08:56 AM EDT, 07/23/2024 (MT Newswires) -- Kane Biotech ( KNBIF ) on Tuesday said the U.S. Food and Drug Administration eliminated its usage limitation on the company's 510(k) cleared revyve Antimicrobial Wound Gel.

Before the removal of this restriction, there was a 90 grams/month limit to the amount of revyve product that could be administered to patients, the company noted.

This now clears the way for the introduction and extended use of Kane's revyve Antimicrobial Wound Gel Spray which is expected to be filled in spray cans in a higher quantity making it suitable for application on large wounds.